Trovagene (TROV) Misses Q1 EPS by 7c

Trovagene (NASDAQ: TROV) reported Q1 EPS of ($0.36), $0.07 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $120 thousand versus the consensus estimate of $260 thousand.

For earnings history and earnings-related data on Trovagene (TROV) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
• Amylyx ALS drug shows no serious adverse events in Phase 1 trial